T-DXd
TUXEDO-4: Phase II study of trastuzumab-deruxtecan in HER2-low breast cancer with new or progressing brain metastases
This site is for U.S. Healthcare Professionals only.
Publications
This section includes selected Daiichi Sankyo-sponsored publications.
The content contained is subject to congress/journal copyright permissions. No further reproduction is permitted without permission of the copyright owner.
Information about pipeline compounds or investigational uses of compounds does not imply FDA approval for these compounds or uses, nor does it establish the safety or efficacy of these compounds or uses. There is no guarantee that the pipeline compounds or investigational uses will receive FDA approval. Daiichi Sankyo does not recommend or suggest use of its medicines in a manner inconsistent with FDA-approved labeling.
Edoxaban
Cardiovascular - AF
Two‐year follow‐up of patients with atrial fibrillation receiving edoxaban in routine clinical practice: Results from the global ETNA‐AF program
De Caterina R, Unverdorben M, Chen C, et al.
Clin Cardiol. 2025 Feb;48(3):e70091. doi: 10.1002/clc.70091.
T-DXd
Lung Cancer
Analytical and clinical validation of the plasma-based Guardant360 CDx test for assessing HER2 (ERBB2) mutation status in patients with non-small-cell lung cancer for treatment with trastuzumab deruxtecan in DESTINY-Lung01/02
Qi Z, Tokuhiro S, Odegaard JI, et al.
J Mol Diagn. 2025;27(2):119-129.
T-DXd
Breast Cancer
Quality-adjusted time without symptoms or toxicity analysis of trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer patients based on secondary use of the DESTINY-Breast03 trial
Dennis N, Dunton K, Livings C,et al.
Eur J Cancer. 2024;217:115192. doi: 10.1016/j.ejca.2024.115192
T-DXd
Breast Cancer
Quality-adjusted time without symptoms or toxicity analysis of trastuzumab deruxtecan versus trastuzumab emtansine in HER2- positive metastatic breast cancer patients based on secondary use of the DESTINY-Breast03 trial
Dennis N, Dunton K, Livings C, et al.
Eur J Cancer. 2025 Feb;217:115192. doi: 10.1016/j.ejca.2024.115192.
T-DXd
Breast Cancer
A pooled analysis of trastuzumab deruxtecan in patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer with brain metastases
André F, Cortés J, Curigliano G, et al.
Ann Oncol. 2024;35(12):1169-1180. doi: 10.1016/j.annonc.2024.08.2347.
T-DXd
Breast Cancer
Trastuzumab deruxtecan for the treatment of patients with HER2-positive breast cancer with brain and/or leptomeningeal metastases: an updated overall survival analysis using data from a multicenter retrospective study (ROSET-BM)
Nakayama T, Niikura N, Yamanaka T, et al.
Breast Cancer. 2024;31(6):1184. doi: 10.1007/s12282-024-01632-z.
T-DXd
Tumor-agnostic
Efficacy of trastuzumab deruxtecan in HER2-expressing solid tumors by enrollment HER2 IHC status: Post hoc analysis of DESTINY-PanTumor02
Oaknin A, Lee J-Y, Makker V, et al.
Adv Ther. 2024;41(11):4125-4139. doi: 10.1007/s12325-024-02975-x.
T-DXd
Breast Cancer
A randomized, double-blind, placebo-controlled phase II study of olanzapine-based prophylactic antiemetic therapy for delayed and persistent nausea and vomiting in patients with HER2-positive or HER2-low breast cancer treated with trastuzumab deruxtecan: ERICA study (WJOG14320B)
Sakai H, Tsurutani J, Ozaki Y, et al.
Ann Oncol. 2025;36(1):31-42. doi: 10.1016/j.annonc.2024.09.001.
T-DXd
Breast Cancer
Trastuzumab deruxtecan after endocrine therapy in metastatic breast cancer
Bardia A, Hu X, Dent R, et al.
N Engl J Med. 2024;391(22):2110-2122. doi: 10.1056/NEJMoa2407086
DataSource by Daiichi Sankyo website provides U.S.
healthcare professionals with high quality, fair balanced, evidence-based medical information.
The information provided is for education purposes only and is not intended as medical advice.
Please choose an option below